CyDex, Inc. Licenses Captisol(R) to Sunesis Pharmaceuticals, Inc. for Oncology Drug Candidate

Published: May 03, 2007

LENEXA, Kan.--(BUSINESS WIRE)--CyDex, Inc., a specialty pharmaceutical company developing improved products through innovative drug delivery, today announced an agreement licensing its Captisol® enabling technology to Sunesis Pharmaceuticals, Inc. for formulation of a selective Aurora kinase inhibitor with potent anti-tumor activity across a number of nonclinical human cancer models.

Back to news